Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: A longitudinal, Prospective Trial

Ching Yang Wu; Chia Lin Lee; Ching Feng Wu; Jui Ying Fu; Cheng Ta Yang; Chi Tsung Wen; Yun Hen Liu; Hui Ping Liu; Jason Chia Hsun Hsieh

doi:10.3390/diagnostics10030144

Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: A longitudinal, Prospective Trial

Ching Yang Wu, Chia Lin Lee, Ching Feng Wu, Jui Ying Fu, Cheng Ta Yang, Chi Tsung Wen, Yun Hen Liu, Hui Ping Liu, Jason Chia Hsun Hsieh^*

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

49 Scopus citations

Abstract

Background: The role of circulating tumor cells (CTCs) for predicting the recurrence of cancer in lung cancer patients after surgery remains unclear. Methods: A negatively selected protocol of CTC identification was applied. For all the enrolled patients, CTC testing was performed before and after surgery on the operation day (day 0), postoperative day 1, and day 3. The daily decline and trend of CTCs were analyzed to correlate with cancer relapse. The mixed model repeated measures (MMRM) adjusted by cancer characteristics was applied for statistical significance. Results: Fifty patients with lung mass undergoing surgery were enrolled. Among 41 primary lung cancers, 26 (63.4%) were pathological stage Tis and I. A total of 200 CTC tests were performed. MMRM analysis indicated that surgery could contribute to a CTC decline after surgery in all patients with statistical significance (p = 0.0005). The daily decrease of CTCs was statistically different between patients with and without recurrence (p = 0.0068). An early rebound of CTC counts on postoperative days 1 and 3 was associated with recurrence months later. Conclusion: CTC testing can potentially serve as a tool for minimal residual disease detection in early-staged lung cancer after curative surgery.

Original language	English
Article number	144
Journal	Diagnostics
Volume	10
Issue number	3
DOIs	https://doi.org/10.3390/diagnostics10030144
State	Published - 01 02 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Keywords

Circulating tumor cells
Early detection
Early-stage
Minimal residual disease’ mixed model repeated measures
Non-small cell lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/diagnostics10030144

Cite this

@article{a66704b089104dd69a864d4cefe40166,

title = "Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: A longitudinal, Prospective Trial",

abstract = "Background: The role of circulating tumor cells (CTCs) for predicting the recurrence of cancer in lung cancer patients after surgery remains unclear. Methods: A negatively selected protocol of CTC identification was applied. For all the enrolled patients, CTC testing was performed before and after surgery on the operation day (day 0), postoperative day 1, and day 3. The daily decline and trend of CTCs were analyzed to correlate with cancer relapse. The mixed model repeated measures (MMRM) adjusted by cancer characteristics was applied for statistical significance. Results: Fifty patients with lung mass undergoing surgery were enrolled. Among 41 primary lung cancers, 26 (63.4\%) were pathological stage Tis and I. A total of 200 CTC tests were performed. MMRM analysis indicated that surgery could contribute to a CTC decline after surgery in all patients with statistical significance (p = 0.0005). The daily decrease of CTCs was statistically different between patients with and without recurrence (p = 0.0068). An early rebound of CTC counts on postoperative days 1 and 3 was associated with recurrence months later. Conclusion: CTC testing can potentially serve as a tool for minimal residual disease detection in early-staged lung cancer after curative surgery.",

keywords = "Circulating tumor cells, Early detection, Early-stage, Minimal residual disease{\textquoteright} mixed model repeated measures, Non-small cell lung cancer",

author = "Wu, \{Ching Yang\} and Lee, \{Chia Lin\} and Wu, \{Ching Feng\} and Fu, \{Jui Ying\} and Yang, \{Cheng Ta\} and Wen, \{Chi Tsung\} and Liu, \{Yun Hen\} and Liu, \{Hui Ping\} and Hsieh, \{Jason Chia Hsun\}",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).",

year = "2020",

month = feb,

day = "1",

doi = "10.3390/diagnostics10030144",

language = "英语",

volume = "10",

journal = "Diagnostics",

issn = "2075-4418",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence

T2 - A longitudinal, Prospective Trial

AU - Wu, Ching Yang

AU - Lee, Chia Lin

AU - Wu, Ching Feng

AU - Fu, Jui Ying

AU - Yang, Cheng Ta

AU - Wen, Chi Tsung

AU - Liu, Yun Hen

AU - Liu, Hui Ping

AU - Hsieh, Jason Chia Hsun

N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Background: The role of circulating tumor cells (CTCs) for predicting the recurrence of cancer in lung cancer patients after surgery remains unclear. Methods: A negatively selected protocol of CTC identification was applied. For all the enrolled patients, CTC testing was performed before and after surgery on the operation day (day 0), postoperative day 1, and day 3. The daily decline and trend of CTCs were analyzed to correlate with cancer relapse. The mixed model repeated measures (MMRM) adjusted by cancer characteristics was applied for statistical significance. Results: Fifty patients with lung mass undergoing surgery were enrolled. Among 41 primary lung cancers, 26 (63.4%) were pathological stage Tis and I. A total of 200 CTC tests were performed. MMRM analysis indicated that surgery could contribute to a CTC decline after surgery in all patients with statistical significance (p = 0.0005). The daily decrease of CTCs was statistically different between patients with and without recurrence (p = 0.0068). An early rebound of CTC counts on postoperative days 1 and 3 was associated with recurrence months later. Conclusion: CTC testing can potentially serve as a tool for minimal residual disease detection in early-staged lung cancer after curative surgery.

AB - Background: The role of circulating tumor cells (CTCs) for predicting the recurrence of cancer in lung cancer patients after surgery remains unclear. Methods: A negatively selected protocol of CTC identification was applied. For all the enrolled patients, CTC testing was performed before and after surgery on the operation day (day 0), postoperative day 1, and day 3. The daily decline and trend of CTCs were analyzed to correlate with cancer relapse. The mixed model repeated measures (MMRM) adjusted by cancer characteristics was applied for statistical significance. Results: Fifty patients with lung mass undergoing surgery were enrolled. Among 41 primary lung cancers, 26 (63.4%) were pathological stage Tis and I. A total of 200 CTC tests were performed. MMRM analysis indicated that surgery could contribute to a CTC decline after surgery in all patients with statistical significance (p = 0.0005). The daily decrease of CTCs was statistically different between patients with and without recurrence (p = 0.0068). An early rebound of CTC counts on postoperative days 1 and 3 was associated with recurrence months later. Conclusion: CTC testing can potentially serve as a tool for minimal residual disease detection in early-staged lung cancer after curative surgery.

KW - Circulating tumor cells

KW - Early detection

KW - Early-stage

KW - Minimal residual disease’ mixed model repeated measures

KW - Non-small cell lung cancer

UR - https://www.scopus.com/pages/publications/85081308276

U2 - 10.3390/diagnostics10030144

DO - 10.3390/diagnostics10030144

M3 - 文章

AN - SCOPUS:85081308276

SN - 2075-4418

VL - 10

JO - Diagnostics

JF - Diagnostics

IS - 3

M1 - 144

ER -

Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: A longitudinal, Prospective Trial

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this